Aptinyx Inc.
| NASDAQ: APTX | Healthcare / Biotechnology / USA |
| 0.0635 | +0.0010 | +1.60% | Vol 34.45K | 1Y Perf -77.68% |
| Nov 29th, 2023 15:58 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.0600 | Previous Close | 0.0625 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 2.25 | Analyst Rating | Hold 3.00 | |
| Potential % | 3.44K | Finscreener Ranking | ★★ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★★★ 50.89 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★★ 44.58 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.72 | Earnings Rating | Neutral | |
| Market Cap | 4.30M | Earnings Date | 14th Nov 2023 | |
| Alpha | -0.07 | Standard Deviation | 0.24 | |
| Beta | 1.30 |
Today's Price Range 0.06000.0657 | 52W Range 0.03100.7200 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -2.31% | ||
| 1 Month | 0.00% | ||
| 3 Months | -6.89% | ||
| 6 Months | -10.06% | ||
| 1 Year | -77.68% | ||
| 3 Years | -98.40% | ||
| 5 Years | -99.71% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -45.60 | |||
ROE last 12 Months | -90.04 | |||
ROA (5Y Avg) | -28.10 | |||
ROA last 12 Months | -69.34 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -72.56 | |||
Return on invested Capital Q | -18.05 | |||
Return on invested Capital Y | -16.69 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 0.53 | ||||
| 166.58 | ||||
| - | ||||
| -0.50 | ||||
| -1.01 | ||||
| 0.53 | ||||
| 0.72 | ||||
| -16 143 000.00 | ||||
| Forward PE | -0.64 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 24.70 | ||||
| 27.40 | ||||
| 0.34 | ||||
| 0.51 | ||||
| -33.70 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -7 453.40 | ||||
| -7 400.80 | ||||
| -1 884.40 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -43.34 | ||||
| -34.38 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2023 | -0.23 | -0.31 | -34.78 |
| Q04 2022 | -0.19 | -0.18 | 5.26 |
| Q03 2022 | -0.24 | -0.23 | 4.17 |
| Q02 2022 | -0.29 | -0.26 | 10.34 |
| Q01 2022 | -0.31 | -0.29 | 6.45 |
| Q04 2021 | -0.35 | -0.29 | 17.14 |
| Q03 2021 | -0.31 | -0.31 | 0.00 |
| Q02 2021 | -0.25 | -0.29 | -16.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.05 | 0.00 | - |
| 12/2023 QR | -0.08 | 0.00 | - |
| 12/2023 FY | -0.40 | 0.00 | - |
| 12/2024 FY | -0.10 | 0.00 | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.05 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 34.45K |
| Shares Outstanding | 67.72K |
| Shares Float | 53.65M |
| Trades Count | 14 |
| Dollar Volume | 2.15K |
| Avg. Volume | 51.09K |
| Avg. Weekly Volume | 41.07K |
| Avg. Monthly Volume | 53.86K |
| Avg. Quarterly Volume | 58.33K |
Aptinyx Inc. (NASDAQ: APTX) stock closed at 0.0635 per share at the end of the most recent trading day (a 1.6% change compared to the prior day closing price) with a volume of 34.45K shares and market capitalization of 4.30M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 43 people. Aptinyx Inc. CEO is Norbert G. Riedel.
The one-year performance of Aptinyx Inc. stock is -77.68%, while year-to-date (YTD) performance is -77.74%. APTX stock has a five-year performance of -99.71%. Its 52-week range is between 0.031 and 0.72, which gives APTX stock a 52-week price range ratio of 4.72%
Aptinyx Inc. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 0.53, a price-to-sale (PS) ratio of 166.58, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -69.34%, a ROC of -72.56% and a ROE of -90.04%. The company’s profit margin is -%, its EBITDA margin is -7 400.80%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aptinyx Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.05 for the next earnings report. Aptinyx Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aptinyx Inc. is Hold (3), with a target price of $2.25, which is +3 443.31% compared to the current price. The earnings rating for Aptinyx Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptinyx Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptinyx Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.34, ATR14 : 0.00, CCI20 : 0.96, Chaikin Money Flow : 0.37, MACD : 0.00, Money Flow Index : 61.77, ROC : 1.63, RSI : 47.20, STOCH (14,3) : 70.09, STOCH RSI : 0.00, UO : 56.27, Williams %R : -29.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptinyx Inc. in the last 12-months were:
Aptinyx Inc.
Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. Its pipeline products are NYX-2925, NYX-458, and NYX-783. NYX-2925 is a novel, oral, small-molecule NMDA receptor modulator in clinical development as a therapy for chronic pain. NYX-2925 works by enhancing synaptic plasticity, a mechanism uniquely suited to addressing chronic pain, and NYX-783 is an NMDA receptor modulating small molecule in clinical development as a therapy for post-traumatic stress disorder.
CEO: Norbert G. Riedel
Telephone: +1 847 871-0377
Address: 909 Davis Street, Evanston 60201, IL, US
Number of employees: 43
